Identification and therapeutic management of highly sensitized patients undergoing renal transplantation

Lu Huber, Nils Lachmann, Michael Drr, Mareen Matz, Lutz Liefeldt, Hans H. Neumayer, Constanze Schnemann, Klemens Budde

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Sensitization is generally referred to as the development of alloantibodies, specifically anti-human leukocyte antigen (HLA) immunoglobulin G (IgG) antibodies, most commonly caused by pregnancy, blood transfusion or a previous transplant. Despite being a well known phenomenon, there has not been a general consensus on its definition, monitoring or management. Today, 25 of the patients waitlisted for kidney transplant in the US have a panel reactive antibody (PRA) of >10 while, in the Eurotransplant zone, 14 have a PRA of >5. Sensitized patients have more difficulty in finding a well HLA-matched donor, and have a higher risk of experiencing longer waiting times, more rejection episodes and eventually inferior long-term graft or patient survival. We review the currently available strategies in identifying and managing highly sensitized patients undergoing renal transplantation. We discuss the progress and limitations in laboratory techniques to elaborate on challenges in defining sensitized patients. The main management options (i.e. the Acceptable Mismatch Program, donor exchange programmes and the desensitization approach) and their mechanisms, related policies, advantages and outcomes, as well as medications and methods being investigated, are updated. In addition, particular emphasis is given to sensitization prevention, a practice that is neglected with our increasing ability to suppress the immune system.

Original languageEnglish (US)
Pages (from-to)1335-1354
Number of pages20
JournalDrugs
Volume72
Issue number10
DOIs
StatePublished - Jul 5 2012

Fingerprint

Kidney Transplantation
HLA Antigens
Transplants
Antibodies
Tissue Donors
Therapeutics
Isoantibodies
Blood Transfusion
Immune System
Immunoglobulin G
Kidney
Pregnancy
Survival

Keywords

  • Alemtuzumab
  • Atacicept
  • Azathioprine
  • Belimumab
  • Bortezomib
  • Ciclosporin
  • Corticosteroids
  • Eculizumab
  • Epratuzumab
  • Everolimus
  • HLA-antigens
  • Immune-globulin
  • Muromonab-CD3
  • Mycophenolate
  • Ocrelizumab
  • Ofatumumab
  • Renal-transplant
  • Rituximab
  • Siplizumab
  • Tacrolimus

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Huber, L., Lachmann, N., Drr, M., Matz, M., Liefeldt, L., Neumayer, H. H., ... Budde, K. (2012). Identification and therapeutic management of highly sensitized patients undergoing renal transplantation. Drugs, 72(10), 1335-1354. https://doi.org/10.2165/11631110-000000000-00000

Identification and therapeutic management of highly sensitized patients undergoing renal transplantation. / Huber, Lu; Lachmann, Nils; Drr, Michael; Matz, Mareen; Liefeldt, Lutz; Neumayer, Hans H.; Schnemann, Constanze; Budde, Klemens.

In: Drugs, Vol. 72, No. 10, 05.07.2012, p. 1335-1354.

Research output: Contribution to journalArticle

Huber, L, Lachmann, N, Drr, M, Matz, M, Liefeldt, L, Neumayer, HH, Schnemann, C & Budde, K 2012, 'Identification and therapeutic management of highly sensitized patients undergoing renal transplantation', Drugs, vol. 72, no. 10, pp. 1335-1354. https://doi.org/10.2165/11631110-000000000-00000
Huber, Lu ; Lachmann, Nils ; Drr, Michael ; Matz, Mareen ; Liefeldt, Lutz ; Neumayer, Hans H. ; Schnemann, Constanze ; Budde, Klemens. / Identification and therapeutic management of highly sensitized patients undergoing renal transplantation. In: Drugs. 2012 ; Vol. 72, No. 10. pp. 1335-1354.
@article{e5ec1b8db64e416d888040adc1e50aaf,
title = "Identification and therapeutic management of highly sensitized patients undergoing renal transplantation",
abstract = "Sensitization is generally referred to as the development of alloantibodies, specifically anti-human leukocyte antigen (HLA) immunoglobulin G (IgG) antibodies, most commonly caused by pregnancy, blood transfusion or a previous transplant. Despite being a well known phenomenon, there has not been a general consensus on its definition, monitoring or management. Today, 25 of the patients waitlisted for kidney transplant in the US have a panel reactive antibody (PRA) of >10 while, in the Eurotransplant zone, 14 have a PRA of >5. Sensitized patients have more difficulty in finding a well HLA-matched donor, and have a higher risk of experiencing longer waiting times, more rejection episodes and eventually inferior long-term graft or patient survival. We review the currently available strategies in identifying and managing highly sensitized patients undergoing renal transplantation. We discuss the progress and limitations in laboratory techniques to elaborate on challenges in defining sensitized patients. The main management options (i.e. the Acceptable Mismatch Program, donor exchange programmes and the desensitization approach) and their mechanisms, related policies, advantages and outcomes, as well as medications and methods being investigated, are updated. In addition, particular emphasis is given to sensitization prevention, a practice that is neglected with our increasing ability to suppress the immune system.",
keywords = "Alemtuzumab, Atacicept, Azathioprine, Belimumab, Bortezomib, Ciclosporin, Corticosteroids, Eculizumab, Epratuzumab, Everolimus, HLA-antigens, Immune-globulin, Muromonab-CD3, Mycophenolate, Ocrelizumab, Ofatumumab, Renal-transplant, Rituximab, Siplizumab, Tacrolimus",
author = "Lu Huber and Nils Lachmann and Michael Drr and Mareen Matz and Lutz Liefeldt and Neumayer, {Hans H.} and Constanze Schnemann and Klemens Budde",
year = "2012",
month = "7",
day = "5",
doi = "10.2165/11631110-000000000-00000",
language = "English (US)",
volume = "72",
pages = "1335--1354",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "10",

}

TY - JOUR

T1 - Identification and therapeutic management of highly sensitized patients undergoing renal transplantation

AU - Huber, Lu

AU - Lachmann, Nils

AU - Drr, Michael

AU - Matz, Mareen

AU - Liefeldt, Lutz

AU - Neumayer, Hans H.

AU - Schnemann, Constanze

AU - Budde, Klemens

PY - 2012/7/5

Y1 - 2012/7/5

N2 - Sensitization is generally referred to as the development of alloantibodies, specifically anti-human leukocyte antigen (HLA) immunoglobulin G (IgG) antibodies, most commonly caused by pregnancy, blood transfusion or a previous transplant. Despite being a well known phenomenon, there has not been a general consensus on its definition, monitoring or management. Today, 25 of the patients waitlisted for kidney transplant in the US have a panel reactive antibody (PRA) of >10 while, in the Eurotransplant zone, 14 have a PRA of >5. Sensitized patients have more difficulty in finding a well HLA-matched donor, and have a higher risk of experiencing longer waiting times, more rejection episodes and eventually inferior long-term graft or patient survival. We review the currently available strategies in identifying and managing highly sensitized patients undergoing renal transplantation. We discuss the progress and limitations in laboratory techniques to elaborate on challenges in defining sensitized patients. The main management options (i.e. the Acceptable Mismatch Program, donor exchange programmes and the desensitization approach) and their mechanisms, related policies, advantages and outcomes, as well as medications and methods being investigated, are updated. In addition, particular emphasis is given to sensitization prevention, a practice that is neglected with our increasing ability to suppress the immune system.

AB - Sensitization is generally referred to as the development of alloantibodies, specifically anti-human leukocyte antigen (HLA) immunoglobulin G (IgG) antibodies, most commonly caused by pregnancy, blood transfusion or a previous transplant. Despite being a well known phenomenon, there has not been a general consensus on its definition, monitoring or management. Today, 25 of the patients waitlisted for kidney transplant in the US have a panel reactive antibody (PRA) of >10 while, in the Eurotransplant zone, 14 have a PRA of >5. Sensitized patients have more difficulty in finding a well HLA-matched donor, and have a higher risk of experiencing longer waiting times, more rejection episodes and eventually inferior long-term graft or patient survival. We review the currently available strategies in identifying and managing highly sensitized patients undergoing renal transplantation. We discuss the progress and limitations in laboratory techniques to elaborate on challenges in defining sensitized patients. The main management options (i.e. the Acceptable Mismatch Program, donor exchange programmes and the desensitization approach) and their mechanisms, related policies, advantages and outcomes, as well as medications and methods being investigated, are updated. In addition, particular emphasis is given to sensitization prevention, a practice that is neglected with our increasing ability to suppress the immune system.

KW - Alemtuzumab

KW - Atacicept

KW - Azathioprine

KW - Belimumab

KW - Bortezomib

KW - Ciclosporin

KW - Corticosteroids

KW - Eculizumab

KW - Epratuzumab

KW - Everolimus

KW - HLA-antigens

KW - Immune-globulin

KW - Muromonab-CD3

KW - Mycophenolate

KW - Ocrelizumab

KW - Ofatumumab

KW - Renal-transplant

KW - Rituximab

KW - Siplizumab

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=84863197412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863197412&partnerID=8YFLogxK

U2 - 10.2165/11631110-000000000-00000

DO - 10.2165/11631110-000000000-00000

M3 - Article

C2 - 22747448

AN - SCOPUS:84863197412

VL - 72

SP - 1335

EP - 1354

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 10

ER -